


FORM PTO-1390 (REV02-2005)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET #: 33900-184PUS	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371				U.S. APPLICATION NO. 107552309 <small>(If known, see 37 CFR 1.55)</small>	
INTERNATIONAL APPLICATION NO. PCT/FR2004/000870		INTERNATIONAL FILING DATE 8 April 2004		PRIORITY DATE CLAIMED 10 April 2003	
TITLE OF INVENTION Crosslinking of Low-Molecular Weight and High-Molecular Weight Polysaccharides; Preparation of Injectable Monophase Hydrogels; Polysaccharides and Hydrogels Obtained					
APPLICANT(S) FOR DO/EO/US Pierre LEBRETON					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: <ol style="list-style-type: none"> <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371 <input checked="" type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). <input type="checkbox"/> The US has been elected (Article 31). <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ol style="list-style-type: none"> <input checked="" type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). <input type="checkbox"/> has been transmitted by the International Bureau. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US) <input checked="" type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). <ol style="list-style-type: none"> <input checked="" type="checkbox"/> is attached hereto. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4). <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). <input type="checkbox"/> have been transmitted by the International Bureau. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. <input checked="" type="checkbox"/> have not been made and will not be made. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). <p>Items 11. to 20. Below concern other document(s) or information included:</p> <ol style="list-style-type: none"> <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. <input checked="" type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. <input checked="" type="checkbox"/> A preliminary amendment. <input type="checkbox"/> An Application Data Sheet under 37 CFR 1.76. <input type="checkbox"/> A substitute specification. <input type="checkbox"/> A power of attorney and/or address letter. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13^{ter}.2 and 37 CFR 1.821-1.825 <input type="checkbox"/> A second copy of the published International Application under 35 U.S.C. 154(d)(4). <input type="checkbox"/> A second copy of the English language translation of the International Application under 35 U.S.C. 154(d)(4). <input checked="" type="checkbox"/> Other items or information: (<i>specify</i>): Int'l Preliminary Examination Report, Int'l Search Report and PCT Request 					

U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) 10/552309		INTERNATIONAL APPLICATION NO. PCT/FR2004/000870		ATTORNEY'S DOCKET NUMBER 33900-184PUS	
The following fees are submitted:					
21. <input checked="" type="checkbox"/> Basic National Fee (37 CFR 1.492(a)(1)-(5))				\$300	\$ 300
<input checked="" type="checkbox"/> Examination Fee					
If International preliminary examination report is prepared by USPTO and all claims satisfy the provisions of PCT article 33(1)-(4)				\$0	\$ 200
All other situations				\$200	
22. <input checked="" type="checkbox"/> Search Fee					
If International preliminary examination report is prepared by USPTO and all claims satisfy the provisions of PCT article 33(1)-(4)				\$0	\$ 400
Search fee (37 CFR 1.445(a)(2)) has been paid on the International application to the USPTO as an International Searching Authority				\$100	
International Search Report prepared and provided to the Office or previously provided to the office				\$400	
All other situations				\$500	
ENTER APPROPRIATE BASIC FEE AMOUNT (total of 21, 22 and 23) =					\$ 900
<input type="checkbox"/> Application Fee for specification and drawing filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.					
Total Sheets	Extra Sheets	Number of additional 50 or fraction thereof (round up to a whole number)		RATE	
-100 =	/50 =			x \$250	
Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(h)).					\$
Claims	Number Filed	Number Extra	RATE		
Total Claims	16 - 20 =	0	x \$ 50.00		
Independent Claims	1 - 3 =	0	x \$200.00		
Multiple dependent claim(s) (if applicable)			+ \$360.00		
TOTAL OF ABOVE CALCULATIONS =					\$ 900
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. Fees above are reduced by 1/2.					\$
SUBTOTAL =					\$ 900
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(i)).					\$
TOTAL NATIONAL FEE =					\$ 900
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by the appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property					\$ 40
TOTAL FEES ENCLOSED					\$940
Amount to be refunded:					\$
Amount to be charged:					\$
a. <input checked="" type="checkbox"/> A check in the amount of \$ 940 to cover the above fees is enclosed.					
b. <input type="checkbox"/> Please charge my Deposit Account No. 03-2412 in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed.					
c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 03-2412. A duplicate copy of this sheet is enclosed.					
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO: Martin B. Pavane Cohen, Pontani, Lieberman & Pavane 551 Fifth Avenue, Suite 1210 New York, New York 10176			 Edward M. Weisz Registration Number: 37,257 October 7, 2005 Tel: (212) 687-2770		

TO did not receive the following listed item(s) NO Assignment Document

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re National Phase PCT Application of

Pierre LEBRETON

Int'l PCT Appln. No.: PCT/FR2004/000870

Int'l Filing Date: 8 April 2004

For: Crosslinking of Low-Molecular
Weight and High-Molecular
Weight Polysaccharides;
Preparation of Injectable
Monophase Hydrogels;
Polysaccharides and Hydrogels
Obtained

Check box if applicable:

☐ DUPLICATE

**GENERAL AUTHORIZATION FOR PAYMENT OF FEES
AND PETITIONS FOR EXTENSIONS OF TIME**

Submit an original and a duplicate for fee processing

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The Commissioner is hereby authorized to credit overpayments or charge the following fees to Deposit Account No. 03-2412

- ☒ Any filing fees required under 37 CFR §1.16.
- ☒ Any patent application processing fees under 37 CFR §1.17 not otherwise paid by check.
- ☒ The issue fee set in 37 CFR 1.18 at 3 months from mailing of the Notice of Allowance, pursuant to 37 CFR 1.311 (b) provided the fee has not already been paid by check.
- ☒ Any filing fees under 37 CFR 1.16 for presentation of extra claims.

Respectfully submitted,
COHEN, PONTANI, LIEBERMAN & PAVANE

By


Edward M. Weisz

Reg. No. 37,257

551 Fifth Avenue, Suite 1210

New York, New York 10176

(212) 687-2770

Dated: October 7, 2005

10/552309

By Express Mail

JC20 Rec'd PCT/PTO 07 OCT 2005

APPLICANT: Pierre LEBRETON

TITLE: CROSSLINKING OF LOW-MOLECULAR WEIGHT AND HIGH-MOLECULAR WEIGHT
POLYSACCHARIDES; PREPARATION OF INJECTABLE MONOPHASE HYDROGELS;
POLYSACCHARIDES AND HYDROGELS OBTAINED.

U.S. COMPLETION OF

INTERNATIONAL APPLICATION PCT/FR2004/000870 FILED APRIL 8, 2004

VERIFICATION OF A TRANSLATION

I, (name and address of translator) Marie-Claude NIEPS of 158, rue de
l'Université, 75007 PARIS - FRANCE hereby declare that:

My name and post office address are as stated above:

That I am knowledgeable in the English Language and the French Language and
that I believe the English translation of the specification, claims, and abstract relating to
International Application PCT/FR2004/000870
filed APRIL 8, 2004 is a true and complete translation.

I hereby declare that all statements made herein of my own knowledge are true
and that all statements made on information and belief are believed to be true, and
further that these statements were made with the knowledge that willful false
statements and the like so made are punishable by fine or imprisonment, or both, under
Section 1001 of Title 18 of the United States Code and that such willful false
statements may jeopardize the validity of the application or any patent issued thereon.


(signature of translator)

Date SEPTEMBER 20, 2005